NNZ2591 is a new molecule so trials would have to be repeated at great cost to Acadia, this, in addition to reducing the patent clock on Trofenitide, which Acadia have paid for makes no financial sense.
Acadia, I believe, will maximize Trofenitide sales while has patent and orphan drug protection and then develop NNZ2591 later to follow on.
Theres nothin stopping them moving straight into Fragike X with 2591, which is where I’d be placing my efforts if I was them, in conjunction with maximizing Daybue sales across the world.
NNZ2591 is a new molecule so trials would have to be repeated at...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.56 |
Change
-0.360(2.59%) |
Mkt cap ! $1.733B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $6.421M | 470.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1643 | $13.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.61 | 3100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |